Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine.

Koga N, Moriya F, Waki K, Yamada A, Itoh K, Noguchi M.

Cancer Sci. 2017 Dec;108(12):2326-2332. doi: 10.1111/cas.13397. Epub 2017 Oct 3.

2.

Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer.

Waki K, Kawano K, Tsuda N, Ushijima K, Itoh K, Yamada A.

J Immunol Res. 2017;2017:1423683. doi: 10.1155/2017/1423683. Epub 2017 Apr 27.

3.

Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination.

Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Sugawara S, Takamori S, Itoh K, Yamada A.

Oncol Lett. 2017 Feb;13(2):993-999. doi: 10.3892/ol.2016.5467. Epub 2016 Dec 7.

4.

Personalized peptide vaccine for cancer treatment; now and its future.

Waki K, Yamada A.

Nihon Rinsho. 2017 Feb;75(2):251-256. Japanese.

PMID:
30562860
5.

Blockade of high mobility group box 1 augments antitumor T-cell response induced by peptide vaccination as a co-adjuvant.

Waki K, Yamada A.

Cancer Sci. 2016 Dec;107(12):1721-1729. doi: 10.1111/cas.13084. Epub 2016 Dec 18.

6.

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy.

Kawano K, Tsuda N, Waki K, Matsueda S, Hata Y, Ushijima K, Itoh K, Yamada A, Kamura T.

Cancer Sci. 2015 Sep;106(9):1111-7. doi: 10.1111/cas.12729. Epub 2015 Jul 22.

7.

Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.

Yamada T, Terazaki Y, Sakamoto S, Yoshiyama K, Matsueda S, Komatsu N, Waki K, Yamada A, Kawahara A, Kage M, Sugawara S, Yamashita Y, Sasada T, Takamori S, Itoh K.

Int J Oncol. 2015 Jan;46(1):55-62. doi: 10.3892/ijo.2014.2699. Epub 2014 Oct 7.

PMID:
25310280
8.

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer.

Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Matsueda S, Komatsu N, Sugawara S, Takamori S, Itoh K, Yamada A.

Cancer Sci. 2014 Oct;105(10):1229-35. doi: 10.1111/cas.12502. Epub 2014 Sep 23.

9.

MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production.

Chen AK, Sengupta P, Waki K, Van Engelenburg SB, Ochiya T, Ablan SD, Freed EO, Lippincott-Schwartz J.

Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2676-83. doi: 10.1073/pnas.1408037111. Epub 2014 Jun 17.

10.

Distribution of ESCRT machinery at HIV assembly sites reveals virus scaffolding of ESCRT subunits.

Van Engelenburg SB, Shtengel G, Sengupta P, Waki K, Jarnik M, Ablan SD, Freed EO, Hess HF, Lippincott-Schwartz J.

Science. 2014 Feb 7;343(6171):653-6. doi: 10.1126/science.1247786. Epub 2014 Jan 16.

11.

A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition.

Keller PW, Huang RK, England MR, Waki K, Cheng N, Heymann JB, Craven RC, Freed EO, Steven AC.

J Virol. 2013 Dec;87(24):13655-64. doi: 10.1128/JVI.01408-13. Epub 2013 Oct 9.

12.

Structural and functional insights into the HIV-1 maturation inhibitor binding pocket.

Waki K, Durell SR, Soheilian F, Nagashima K, Butler SL, Freed EO.

PLoS Pathog. 2012;8(11):e1002997. doi: 10.1371/journal.ppat.1002997. Epub 2012 Nov 8.

13.

Combinational sensitization of Leishmania with uroporphyrin and aluminum phthalocyanine synergistically enhances their photodynamic inactivation in vitro and in vivo.

Dutta S, Waki K, Chang KP.

Photochem Photobiol. 2012 May-Jun;88(3):620-5. doi: 10.1111/j.1751-1097.2012.01076.x. Epub 2012 Jan 25.

14.

Macrophages and Cell-Cell Spread of HIV-1.

Waki K, Freed EO.

Viruses. 2010 Aug 1;2(8):1603-1620.

15.

Myristate exposure in the human immunodeficiency virus type 1 matrix protein is modulated by pH.

Fledderman EL, Fujii K, Ghanam RH, Waki K, Prevelige PE, Freed EO, Saad JS.

Biochemistry. 2010 Nov 9;49(44):9551-62. doi: 10.1021/bi101245j.

16.

Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO.

J Virol. 2009 May;83(10):4884-94. doi: 10.1128/JVI.02659-08. Epub 2009 Mar 11.

17.
18.

Consistence of miniexon polymerase chain reaction-restriction fragment length polymorphism and single-copy gene sequence analyses in discriminating Leishmania genotypes.

Serin MS, Waki K, Chang KP, Aslan G, Direkel S, Otag F, Kayar B, Koksal F, Emekdas G.

Diagn Microbiol Infect Dis. 2007 Mar;57(3):295-9. Epub 2006 Dec 1.

PMID:
17141456
19.

Emergence of zoonotic canine leishmaniasis in the United States: isolation and immunohistochemical detection of Leishmania infantum from foxhounds from Virginia.

Rosypal AC, Troy GC, Zajac AM, Duncan RB Jr, Waki K, Chang KP, Lindsay DS.

J Eukaryot Microbiol. 2003;50 Suppl:691-3.

PMID:
14736222

Supplemental Content

Loading ...
Support Center